For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Vyndamax and Attruby represents a significant breakthrough . These novel therapies preserve the transthyretin protein, halting its damaging build-up and lessening the severity of the